Day: June 9, 2020

AIM & TSX:  “TGL” & NASDAQ:  “TGA”CALGARY, Alberta, June 09, 2020 (GLOBE NEWSWIRE) — TransGlobe Energy Corporation (“TransGlobe” or the “Company”) announces that the Company will be participating at the upcoming Virtual Summer Summit June 9 to June 12, 2020.  TransGlobe will be presenting on Wednesday, June 10, 2020 at 10:20 am EDT/3:20 pm BST.Interested persons may access the webcast at:https://www.webcaster4.com/Webcast/Page/2038/35051About TransGlobeTransGlobe Energy Corporation is a cash flow focused oil and gas exploration and development company whose current activities are concentrated in the Arab Republic of Egypt and Canada. TransGlobe’s common shares trade on the Toronto Stock Exchange and the AIM market of the London Stock Exchange under the symbol TGL and on the NASDAQ Exchange under the symbol TGA.

Patient enrollment completed; 50 patients in the trialEncouraging preliminary results based on interim dataUnmet medical need confirmed by FDALYON, France and CAMBRIDGE, Mass., June 09, 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today provided an update on the ongoing Phase 2 trial, sponsored by the Nordic Society of Paediatric Haematology and Oncology (NOPHO) of eryaspase in second-line acute lymphoblastic leukemia (ALL) patients.The NOR-GRASPALL-2016 trial is evaluating the safety and activity of eryaspase in primarily pediatric acute lymphoblastic leukemia (ALL) patients who developed hypersensitivity reactions to pegylated asparaginase.  The trial which is...

Fin du recrutement des 50 patients de l’étudeRésultats préliminaires encourageants d’après les données intérimairesConfirmation du besoin médical insatisfait par la Food and Drug Administration (FDA) LYON, France et CAMBRIDGE, États-Unis, 09 juin 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Euronext : ERYP ; Nasdaq : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant des médicaments dans les globules rouges, fait aujourd’hui le point sur l’étude de phase II conduite par l’Organisation nordique d’hématologie et d’oncologie pédiatrique (NOPHO), avec eryaspase en traitement de seconde ligne de la leucémie aiguë lymphoblastique (LAL).L’étude NOR-GRASPALL-2016 évalue la sécurité et l’efficacité d’eryaspase, principalement chez les enfants atteints de leucémie aiguë lymphoblastique...

NoHo Partners PlcNOHO PARTNERS PLCS’S INTERIM REPORT 1 JANUARY–31 MARCH 2020The coronavirus pandemic had a strong impact on the business environment — the Group initiated determined adjustment measuresIn March 2020, the Group’s business stopped almost entirely due to the market collapse caused by the coronavirus pandemic. The turnover of the restaurant business for January–February 2020 increased in line with expectations, by approximately MEUR 7.5 compared to the corresponding period in the previous year, while EBIT grew by about MEUR 0.6. The result of the restaurant business decreased by MEUR 9.0 in March due to turnover decreasing MEUR 10.7 from the corresponding month in the previous year due because of the market disruption, and the adjustment measures launched by the company did not yet have effects on the result for March. The...

NoHo Partners OyjNOHO PARTNERS OYJ:N OSAVUOSIKATSAUS 1.1.–31.3.2020Koronapandemia vaikutti voimakkaasti liiketoimintaympäristöön – yhtiö aloitti määrätietoiset sopeuttamistoimetMaaliskuussa 2020 koronaviruspandemian aiheuttaman markkinaromahduksen johdosta konsernin liiketoiminta pysähtyi lähes täysin. Ravintolaliiketoiminnan tammi–helmikuun 2020 liikevaihto kasvoi odotusten mukaisesti noin 7,5 miljoonaa euroa viime vuoden vastaavasta jaksosta ja liikevoitto kasvoi noin 0,6 miljoonaa euroa. Ravintolaliiketoiminnan tulos supistui maaliskuussa 9,0 miljoonaa euroa, koska liikevaihto laski markkinahäiriön vuoksi viime vuoden vastaavasta kuukaudesta 10,7 miljoonaa euroa, eivätkä yhtiön käynnistämät sopeuttamistoimenpiteet ehtineet vielä vaikuttaa maaliskuun tulokseen. Yhtiö reagoi välittömästi markkinahäiriön ilmetessä aloittaen määrätietoiset...

In May 2020, AS LHV Group earned a net profit of EUR 2.8 million. AS LHV Pank earned EUR 2.6 million and AS LHV Varahaldus EUR 0.3 million as net profit.After an unsettled April due to the emergency situation, May was characterized by recovering business volumes and moving towards the finishing line with many important projects. The loan portfolio, deposits as well as volume of funds are all increasing. Corporate loan portfolio increased by EUR 12 million and retail loan portfolio grew by EUR 10 million. Consolidated deposits increased by EUR 159 million, including payments intermediaries deposits by EUR 116 million and retail deposits by EUR 17 million.Otherwise normal month regarding revenue and expenses was influenced by the EUR 0.3 million financial expense from the revaluation of the liquidity portfolio of the bank. Because of the...